This is the third (actually second) new Alzheimer's drug of the last 3 or so years.
Aducanumab - The first one, and possibly the most useless of them. The newest studies say reduces degradation by 2%
Lecanemab - The second, reduces degradation by 27%
Donanemab - This newest drug, reduces degradation by 35%
All three are based on the same mechanisms, so I don't know if you could double-dip on medications.